Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

Author: Edlund Per   Ahlgren Johan   Bjerre Karsten   Andersson Michael   Bergh Jonas   Mouridsen Henning   Holmberg Stig B.   Bengtsson Nils-Olof   Jakobsen Erik   Møøller Susanne   Lindman Henrik   Blomqvist Carl  

Publisher: Informa Healthcare

ISSN: 0284-186X

Source: Acta Oncologica, Vol.50, Iss.3, 2011-04, pp. : 329-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content